BLOOMFIELD, N.J., April 16 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL - News) today announced that in vivo and in vitro preclinical data presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting show that ONCONASE (ranpirnase) significantly inhibits tumor growth of non-small cell lung cancer (NSCLC) and breast cancer cells.
